Long-Term Effect of Varenicline (Chantix®) in Four Ataxic Patients: Prolonged Symptomatic Benefit Following Drug Discontinuation

  • Theresa A. Zesiewicz
  • , Kelly L. Sullivan
  • , Amber M. Miller
  • , L. E. Dempsey
  • , Israt Jahan
  • , L. Wecker

Research output: Contribution to book or proceeding › Chapter

Abstract

This conference abstract was published in the Proceedings of the World Congress on Parkinson’s Disease and Related Disorders .
Original languageAmerican English
Title of host publicationProceedings of the World Congress on Parkinson’s Disease and Related Disorders
StatePublished - Dec 12 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Disciplines

  • Epidemiology
  • Public Health

Keywords

  • Ataxic patients
  • Chantix®
  • Drug discontinuation
  • Long-term effect
  • Prolonged symptomatic benefit
  • Varenicline

Cite this